KALA BIO, Inc. KALA
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -4.54% | -82.34% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.50% | -82.38% | |||
| Operating Income | 4.50% | 82.38% | |||
| Income Before Tax | 2.47% | -336.30% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 2.47% | -336.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.47% | -336.30% | |||
| EBIT | 4.50% | 82.38% | |||
| EBITDA | 4.70% | 83.06% | |||
| EPS Basic | 24.25% | -105.05% | |||
| Normalized Basic EPS | 24.27% | 99.56% | |||
| EPS Diluted | 24.25% | -105.05% | |||
| Normalized Diluted EPS | 24.27% | 99.56% | |||
| Average Basic Shares Outstanding | 28.75% | 4,580.17% | |||
| Average Diluted Shares Outstanding | 28.75% | 4,580.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||